Citations

Clear

1526 citation(s) found for "Sun, Yu".

Sensitization of Tumor Cells to IFNy-Mediated Cell Death
Sun, N , Krogman, Erica N., Ting, Adrian T. , Chawla, Yogesh

Mayo Clinic

The Journal of Immunology | August 10, 2023 | Volume: 210 | Issue: Supplement_1 | Pages: 245.22-245.22

10.4049/jimmunol.210.supp.245.22 Get It

Abstract There is increasing evidence that immunotherapies make tumor cells more vulnerable to the host’s own immune system that can lead to long-term and durable remission. To date, only a small percentage of cancer patients have benefited from this approach and advances in this field will likely come from a greater understanding of the interaction between immune cells and their tumor targets. T cells are critical to a successful anti-tumor response due to their ability to directly lyse tumor cells by releasing cytolytic granules, and to produce inflammatory cytokines, such as interferon gamma (IFNγ). IFNγ has several functions in an anti-tumor response. On the immune cell side, IFNγ is a major driver of Th1 differentiation that leads to the activation of T cells and NK cells. On the tumor side, IFNγ can enhance MHC class I presentation but also inhibitory receptors such as PD-1. However, it is not as clear whether IFNγ is directly cytotoxic for tumor cells. If that is the case, it is also likely that due to selection pressure exerted by T cells, tumor cells may have acquired mechanisms to protect themselves against this possibility. Thus, I hypothesized that tumor cells are normally resistant to killing by IFNγ but can be sensitized if the death protection mechanisms are disabled. In preliminary studies using the B16F1 murine melanoma model, we found that while wild-type (WT) melanoma cells were completely resistant, tumor cells with knockouts of two kinases (DKO) became highly sensitized to IFNγ-mediated apoptotic death. Furthermore, the DKO tumors were also more easily killed by T cells in an IFNγ-dependent manner. These findings will provide insight into potential targets for therapeutic intervention to enhance immune-mediated destruction of tumors.
Time Course scRNAseq Analysis Reveals Mechanisms of Impaired Lung Recovery Post Influenza Infection during Aging: Zooming into Macrophages
Wu, Yue , Gao, Xiaochen , Li, Ying , Fain, Cori E. , Johnson, Aaron J. , Tang, Jinyi , Li, Chaofan , Zhu, Bibo , Santos, Gislane de Almeida , Narasimhan, Harish , Zhang, Ruixuan , Ayasoufi, Katayoun , Johnson, Aaron J. , Dong, Haidong , Sun, Jie

Mayo Clinic

The Journal of Immunology | August 10, 2023 | Volume: 210 | Issue: Supplement_1 | Pages: 71.24-71.24

10.4049/jimmunol.210.supp.71.24 Get It

Abstract Aging is considered to be a major risk factor for host morbidity and mortality upon acute respiratory virus infections. To better elucidate the immune determinants of viral pathogenesis during aging, we chronological characterized lung cellular and molecular profiles following influenza virus (PR8) infection in young or aged mice till 60 days post infection. Time-course scRNAseq coupled with high dimensional flow cytometry enabled the description of changes in both immune and stromal compartment between young and aged hosts. We further zoomed into the myeloid compartment and focused on the dynamic responses of lung macrophages given their complex roles in viral pathogenesis, tissue repair and lung fibrosis. Enlarged Monocyte-derived Macrophage (MoM) population as well as decreased resident-Alveolar Macrophage (AM) population were observed in the aged mice when compared to those of the young mice. Despite the self-sustain nature of AMs during homeostasis, it has been reported that Ly6Chi monocytes can gain AM identity following severe lung damage like influenza virus infection. We found that the gain of AM identity from monocytes was abrogated in the aged hosts, which likely contributed to the age-associated impairment in lung recovery after influenzas virus infection. Additionally, trajectory analysis with scRNAseq allowed us to identify IFNα/γ signaling to be potential pathways contributing to such defect. This notion is also supported by elevated IFNγ level in BAL from the aged host during lung recovery. Our results thus have improved our understanding on the cellular and molecular mechanisms by which aged hosts exhibit severe diseases and delayed recovery after respiratory viral infection.
Adolescent and Young Adult (AYA) Oncology, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Pappo, Alberto S. , Acquazzino, Melissa , Barnett, Marie , Casey, Robert, Choo, Sun , Dinner, Shira, Fair, Douglas , Federman, Noah , Folbrecht, Jeanelle , Gandhi, Shipra , Germann, Julie N. , Goldsby, Robert E. , Hayashi, Robert J. , Huang, Mary , Jacobs, Linda A. , Lee‐Miller, Cathy , Link, Michael P., Lustberg, Maryam B. , Malogolowkin, Marcio H., Oeffinger, Kevin C. , Pratilas, Christine A. , Mehren, Margaret von , Yeager, Nicholas D. , Hang, Lisa, von Mehren, Margaret , Lustberg, Maryam , Bhatia, Smita , Allen‐Rhoades, Wendy , Borinstein, Scott C. , Chugh, Rashmi , Ermoian, Ralph P. , Huang, Alex Yee-Chen , Livingston, J. Andrew , Reed, Damon R. , Skiles, Jodi L. , Montgomery, Sarah E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 7, 2023 | Volume: 21 | Issue: 8 | Pages: 851-880

10.6004/jnccn.2023.0040 | PMID 37549914 Get It

This selection from the NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology focuses on considerations for the comprehensive care of AYA patients with cancer. Compared with older adults with cancer, AYA patients have unique needs regarding treatment, fertility counseling, psychosocial and behavioral issues, and supportive care services. The complete version of the NCCN Guidelines for Adolescent and Young Adult (AYA) Oncology addresses additional aspects of caring for AYA patients, including risk factors, screening, diagnosis, and survivorship.
A global action agenda for turning the tide on fatty liver disease
Lazarus, Jeffrey V. , Mark, Henry E. , Allen, Alina M. , Arab, Juan Pablo , Carrieri, Patrizia , Noureddin, Mazen , Alazawi, William , Alkhouri, Naim , Alqahtani, Saleh A. , Anstee, Quentin M. , Brennan, Paul , Burra, Patrizia , Castro‐Narro, Graciela , Cortez‐Pinto, Helena , Cusi, Kenneth , Dedes, Nikos, Duseja, Ajay , Gastaldelli, Amalia , Hagström, Hannes , Huang, Terry T.‐K. , Ivancovsky‐Wajcman, Dana , Kautz, Achim, Kopka, Christopher J. , Krag, Aleksander , Newsome, Philip N. , Rinella, Mary E. , Silva, Marcelo , Tsochatzis, Emmanuel , Valenti, Luca , Zelber‐Sagi, Shira , Schattenberg, Jörn M. , Younossi, Zobair M. , Collaborators, on behalf of the Healthy Livers, Healthy Lives, Adams, Leon A. , Wong, Robert J. , Satapathy, Sanjaya K. , Alves‐Bezerra, Michele , Khader, Yousef , Graupera, Isabel , Grønbæk, Henning , Yılmaz, Yusuf , Thiele, Maja , Lazo, Mariana , Hickman, Ingrid J. , Idılman, Ramazan , Kim, Seung Up , Desalegn, Hailemichael , Oliveira, Cláudia P. , Crespo, Javier , Velasco, J.A. Velarde-Ruiz , Goossens, Nicolas , George, Jacob , George, Jacob , Caussy, Cyrielle , Alswat, Khalid , Bataller, Ramon A , Berg, Thomas , Brennan, Paul N , Castro-Narro, Graciela E , Cortez-Pinto, Helena , Duseja, Ajay , Francque, Sven M , Gastaldelli, Amalia , Hagström, Hannes , Huang, Terry T K , Ivancovsky Wajcman, Dana , Kopka, Christopher J , Krag, Aleksander , Newsome, Philip N , Romero, Diana , Sarin, Shiv Kumar , Terrault, Norah , Tsochatzis, Emmanuel A , Valenti, Luca , Schattenberg, Jörn M , Wong, Vincent Wai-Sun , Sathapathy, Sanjaya , Arab, Juan P , Lazarus, Jeffrey V , Wong, Robert J , Allen, Alina M , Anstee, Quentin M , Hickman, Ingrid J , Rinella, Mary , Yilmaz, Yusuf , Thiele, Maja , Lazo, Mariana , Crespo, Javier , Carrieri, Patrizia , Idilman, Ramazan , Goossens, Nicolas , Velarde-Ruiz Velasco, José Antonio , Desalgn, Hailemicheal , George, Jacob , Arrese, Marco , Francque, Sven , Spearman, C Wendy , Terrault, Norah A. , Villota‐Rivas, Marcela , Wong, Vincent Wai‐Sun , Collaborators, on behalf of the Healthy Livers, Healthy Lives

Mayo Clinic

Hepatology | August 4, 2023 | Volume: 79 | Issue: 2 | Pages: 502-523

10.1097/hep.0000000000000545 | PMID 37540183 Get It

Background and Aims: Fatty liver disease is a major public health threat due to its very high prevalence and related morbidity and mortality. Focused and dedicated interventions are urgently needed to target disease prevention, treatment, and care. Approach and Results: We developed an aligned, prioritized action agenda for the global fatty liver disease community of practice. Following a Delphi methodology over 2 rounds, a large panel (R1 n = 344, R2 n = 288) reviewed the action priorities using Qualtrics XM, indicating agreement using a 4-point Likert-scale and providing written feedback. Priorities were revised between rounds, and in R2, panelists also ranked the priorities within 6 domains: epidemiology, treatment and care, models of care, education and awareness, patient and community perspectives, and leadership and public health policy. The consensus fatty liver disease action agenda encompasses 29 priorities. In R2, the mean percentage of “agree” responses was 82.4%, with all individual priorities having at least a super-majority of agreement (> 66.7% “agree”). The highest-ranked action priorities included collaboration between liver specialists and primary care doctors on early diagnosis, action to address the needs of people living with multiple morbidities, and the incorporation of fatty liver disease into relevant non-communicable disease strategies and guidance. Conclusions: This consensus-driven multidisciplinary fatty liver disease action agenda developed by care providers, clinical researchers, and public health and policy experts provides a path to reduce the prevalence of fatty liver disease and improve health outcomes. To implement this agenda, concerted efforts will be needed at the global, regional, and national levels.
AdvanTIG-105: Phase 1b dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy (chemo) in patients (pts) with stage IV gastric/gastroesophageal adenocarcinoma (GC/GEJC).
Kim, Sae Hyun , Shiah, Her‐Shyong, Yoon, Harry H. , Zheng, Hao , Zhou, Ziqi , Wang, Ruihua , Lee, Gyeong‐Won , Shim, Byoung Yong , Frentzas, Sophia , Sun, Meili , Clay, Timothy Dudley , Tan, Wei, Ba, Yi

Mayo Clinic

JCO Global Oncology | August 3, 2023 | Volume: 9 | Issue: Supplement_1 | Pages: 31-31

10.1200/go.2023.9.supplement_1.31 Get It

31 Background: T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) inhibitor in combination with an anti-programmed cell death protein 1 (PD-1) antibody has shown antitumor activity in solid tumors. AdvanTIG-105 (NCT04047862) is a phase 1/1b open-label study designed to assess the safety and preliminary antitumor activity of OCI, an anti-TIGIT monoclonal antibody (mAb), + TIS, an anti-PD-1 mAb, in pts with unresectable, locally advanced or metastatic solid tumors. In the dose-escalation part, OCI + TIS was well tolerated with preliminary antitumor activity observed, and the recommended phase 2 dose (RP2D) of OCI 900 mg intravenously (IV) every three weeks (Q3W) + TIS 200 mg IV Q3W was established. We report results from the dose-expansion part (GC/GEJC Cohort 9) of the AdvanTIG-105 study. Methods: Eligible pts had histologically/cytologically confirmed stage IV GC/GEJC. Pts were excluded if they had squamous cell, undifferentiated or other histological types of GC, had GC/GEJC with positive HER2 expression, or if they had received any prior therapy for metastatic disease. Pts received either the RP2D of OCI + TIS with oxaliplatin + capecitabine Q3W for 6 cycles (C), followed by maintenance therapy with the RP2D of OCI + TIS, + capecitabine Q3W, or the RP2D of OCI + TIS with cisplatin + 5-fluorouracil Q3W for 6 C. Treatment continued until disease progression, intolerable toxicity, or withdrawal of consent. The primary endpoint was investigator-assessed overall response rate (ORR) per RECIST v1.1. Secondary endpoints included progression-free survival (PFS), duration of response (DoR), disease control rate (DCR) per RECIST v1.1, and safety. Results: As of September 29, 2022, 60 pts with a median age of 61.5 years (range 35-82) were enrolled; 59 were efficacy evaluable. Median study follow-up was 31.1 weeks (range 1.4-78.4). ORR was 50.8% (95% CI: 37.5, 64.1); DCR was 84.7% (95% CI: 73.0, 92.8) with a median DoR of 8.1 months (95% CI: 4.5, not evaluable [NE]). Median PFS was 8.2 months (95% CI: 5.8, NE). In a subgroup analysis, ORR in pts with PD-L1 tumor area positivity (TAP) score ≥5% (n=27) was 59.3% (95% CI: 38.8, 77.6), and 50.0% (95% CI: 30.7, 69.4) in pts with PD-L1 TAP <5% (n=28). All 60 pts reported ≥1 treatment-emergent adverse event (TEAE), the most common being anemia (43.3%) and platelet count decreased (41.7%). In total, 43 pts (71.7%) had ≥grade 3 TEAEs and 28 (46.7%) had serious adverse events. TEAEs leading to discontinuation of TIS and OCI occurred in 5 (8.3%) pts. TEAEs led to death in 2 (3.3%) pts; one event (neutropenic sepsis) was related to chemo, while the other (pulmonary embolism) was not treatment related. Conclusions: OCI 900 mg + TIS 200 mg + chemo was generally well tolerated and showed encouraging antitumor activity in pts with stage IV GC/GEJC. Clinical trial information: NCT04047862 .
Androgen Receptor Variants Confer Castration Resistance in Prostate Cancer by Counteracting Antiandrogen-Induced Ferroptosis
Sun, Rui , Yan, Binyuan , Li, Hao , Ding, Donglin , Wang, Liguo , Pang, Jun , Ye, Dingwei , Huang, Haojie , Sun, Rui , Wang, Liguo , Huang, Rui , Yan, Binyuan , Pang, Jun , Ding, Donglin , Sun, Rui

Mayo Clinic

Cancer Research | August 1, 2023 | Volume: 83 | Issue: 19 | Pages: 3192-3204

10.1158/0008-5472.can-23-0285 | PMID 37527336 Get It

Abstract Androgen receptor (AR) inhibition by androgen deprivation and/or antiandrogen administration is the mainstay therapy for advanced prostate cancer. However, most prostate cancers ultimately become resistant to these therapies, indicating the importance of identifying mechanisms driving resistance to improve patient outcomes. Here we demonstrated that acute treatment with the antiandrogen enzalutamide (ENZ) decreased glutathione (GSH) production, increased lipid peroxidation, and induced ferroptosis in prostate cancer cells. Consistently, meta-analysis of transcriptomic data linked the androgen-AR axis to metabolism-related biological processes, including lipid metabolism. The cystine transporter gene SLC7A11 was a key AR target, and full-length AR (AR-FL) transactivated SLC7A11 transcription by directly occupying the SLC7A11 promoter and putative enhancer regions. AR variants (AR-V) preferentially bound the SLC7A11 enhancer and upregulated SLC7A11 expression, thereby conferring resistance to ferroptosis induced by ENZ treatment. However, this effect was abolished following downregulation of AR-Vs using the dual CBP/p300 and BET inhibitor NEO2734. These findings reveal ferroptosis induction as an anticancer mechanism of antiandrogens and SLC7A11 as a direct target gene of AR-FL and AR-Vs. AR-V-mediated SLC7A11 expression represents a mechanism coupling ferroptosis resistance to prostate cancer progression. Significance: Upregulation of SLC7A11 can be induced by androgen receptor variants to inhibit antiandrogen-induced prostate cancer cell ferroptosis and to drive castration resistance in prostate cancer.
Identifying metabolic features of colorectal cancer liability using Mendelian randomization
Bull, Caroline J. , Hazelwood, Emma , Tan, Vanessa Y. , Constantinescu, Andrei‐Emil , Borges, Maria Carolina , Legge, Danny , Burrows, Kimberley , Huyghe, Jeroen R. , Brenner, Hermann , Castellvı́-Bel, Sergi , Li, Li , Pai, Rish K. , Figueiredo, Jane C. , Timpson, Nicholas J. , Vincent, Emma E. , Bull, Caroline J , Tan, Vanessa , Legge, Danny , Huyghe, Jeroen R , Vincent, Emma E , Borges, Maria C , Brenner, Hermann , Castellví-Bel, Sergi , Hazelwood, Emma , Bell, Joshua A. , Chan, Andrew T. , Kweon, Sun-Seog , Marchand, Loı̈c Le , Cheng, Iona C. , Murphy, Neil , Gunter, Marc J.

Mayo Clinic

eLife | July 25, 2023 | Volume: 12 | Issue: No issue available | Pages: No page available

10.7554/elife.87894 | PMID 38127078 Get It

Background: Recognizing the early signs of cancer risk is vital for informing prevention, early detection, and survival. Methods: To investigate whether changes in circulating metabolites characterize the early stages of colorectal cancer (CRC) development, we examined the associations between a genetic risk score (GRS) associated with CRC liability (72 single-nucleotide polymorphisms) and 231 circulating metabolites measured by nuclear magnetic resonance spectroscopy in the Avon Longitudinal Study of Parents and Children (N = 6221). Linear regression models were applied to examine the associations between genetic liability to CRC and circulating metabolites measured in the same individuals at age 8 y, 16 y, 18 y, and 25 y. Results: The GRS for CRC was associated with up to 28% of the circulating metabolites at FDR-P < 0.05 across all time points, particularly with higher fatty acids and very-low- and low-density lipoprotein subclass lipids. Two-sample reverse Mendelian randomization (MR) analyses investigating CRC liability (52,775 cases, 45,940 controls) and metabolites measured in a random subset of UK Biobank participants (N = 118,466, median age 58 y) revealed broadly consistent effect estimates with the GRS analysis. In conventional (forward) MR analyses, genetically predicted polyunsaturated fatty acid concentrations were most strongly associated with higher CRC risk. Conclusions: These analyses suggest that higher genetic liability to CRC can cause early alterations in systemic metabolism and suggest that fatty acids may play an important role in CRC development. Funding: This work was supported by the Elizabeth Blackwell Institute for Health Research, University of Bristol, the Wellcome Trust, the Medical Research Council, Diabetes UK, the University of Bristol NIHR Biomedical Research Centre, and Cancer Research UK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This work used the computational facilities of the Advanced Computing Research Centre, University of Bristol - http://www.bristol.ac.uk/acrc/ .
Identifying metabolic features of colorectal cancer liability using Mendelian randomization
Bull, Caroline J. , Hazelwood, Emma , Tan, Vanessa Y. , Constantinescu, Andrei‐Emil , Borges, Maria Carolina , Legge, Danny , Burrows, Kimberley , Huyghe, Jeroen R. , Li, Li , Pai, Rish K. , Figueiredo, Jane C. , Borges, Maria C , Bull, Caroline J , Legge, Danny , Hazelwood, Emma , Bell, Joshua A. , Brenner, Hermann , Castellvı́-Bel, Sergi , Chan, Andrew T. , Kweon, Sun-Seog , Marchand, Loı̈c Le , Cheng, Iona C. , Murphy, Neil , Gunter, Marc J. , Timpson, Nicholas J. , Vincent, Emma E.

Mayo Clinic

No container title available | July 25, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.87894.1 Get It

Recognizing the early signs of cancer risk is vital for informing prevention, early detection, and survival. To investigate whether changes in circulating metabolites characterise the early stages of colorectal cancer (CRC) development, we examined associations between a genetic risk score (GRS) associated with CRC liability (72 single nucleotide polymorphisms) and 231 circulating metabolites measured by nuclear magnetic resonance spectroscopy in the Avon Longitudinal Study of Parents and Children (N=6,221). Linear regression models were applied to examine associations between genetic liability to colorectal cancer and circulating metabolites measured in the same individuals at age 8, 16, 18 and 25 years. The GRS for CRC was associated with up to 28% of the circulating metabolites at FDR-P<0.05 across all time points, particularly with higher fatty acids and very-low- and low-density lipoprotein subclass lipids. Two-sample reverse Mendelian randomization (MR) analyses investigating CRC liability (52,775 cases, 45,940 controls) and metabolites measured in a random subset of UK Biobank participants (N=118,466, median age 58y) revealed broadly consistent effect estimates with the GRS analysis. In conventional (forward) MR analyses, genetically predicted polyunsaturated fatty acid concentrations were most strongly associated with higher CRC risk. These analyses suggest that higher genetic liability to CRC can cause early alterations in systemic metabolism, and suggest that fatty acids may play an important role in CRC development.